Altimmune, Inc. (NASDAQ:ALT) Stake Lifted by Bellevue Group AG

Bellevue Group AG increased its position in shares of Altimmune, Inc. (NASDAQ:ALT) by 43.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 863,660 shares of the company’s stock after purchasing an additional 263,660 shares during the period. Bellevue Group AG owned 1.22% of Altimmune worth $5,303,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Larson Financial Group LLC bought a new position in shares of Altimmune during the 3rd quarter valued at about $31,000. CANADA LIFE ASSURANCE Co bought a new stake in Altimmune during the first quarter worth approximately $44,000. Horizon Wealth Management LLC acquired a new position in Altimmune in the second quarter worth approximately $66,000. PFG Investments LLC acquired a new position in Altimmune in the second quarter worth approximately $67,000. Finally, Principal Financial Group Inc. bought a new position in shares of Altimmune in the second quarter valued at $70,000. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Price Performance

Shares of Altimmune stock opened at $8.57 on Friday. Altimmune, Inc. has a 1 year low of $3.16 and a 1 year high of $14.84. The stock has a 50-day moving average price of $7.21 and a 200 day moving average price of $6.98.

Altimmune (NASDAQ:ALT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The business had revenue of $0.01 million for the quarter. During the same period in the previous year, the firm earned ($0.39) earnings per share. On average, equities analysts forecast that Altimmune, Inc. will post -1.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. UBS Group started coverage on Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective for the company. Evercore ISI upgraded Altimmune to a “strong-buy” rating in a research report on Friday, August 9th. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Altimmune in a report on Thursday, November 14th. Finally, B. Riley reiterated a “buy” rating and issued a $20.00 target price on shares of Altimmune in a report on Monday, August 12th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.